BiotechTube

PLN-74809

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Pulmonary Fibrosis

Conditions

Idiopathic Pulmonary Fibrosis

Trial Timeline

Feb 13, 2020 → Jul 5, 2022

NCT ID
NCT04072315

About PLN-74809

PLN-74809 is a phase 2 stage product being developed by Pliant Therapeutics for Idiopathic Pulmonary Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04072315. Target conditions include Idiopathic Pulmonary Fibrosis.

What happened to similar drugs?

20 of 20 similar drugs in Idiopathic Pulmonary Fibrosis were approved

Approved (20) Terminated (1) Active (0)
✅Tirzepatide + Tirzepatide PlaceboEli LillyApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved
✅Omalizumab + PlacebosNovartisApproved
✅Nintedanib + PirfenidoneRocheApproved
✅Tocilizumab + NSAIDs + CSs + MTXRocheApproved
✅TocilizumabRocheApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04072315Phase 2Completed

Competing Products

20 competing products in Idiopathic Pulmonary Fibrosis

See all competitors
ProductCompanyStageHype Score
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 2
32
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
50
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
Zimura + EyleaAstellas PharmaPhase 2
27
Avacincaptad PegolAstellas PharmaPhase 2
35
Rituximab + cyclosporineSun PharmaceuticalPhase 3
32
E5501EisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
PerampanelEisaiPre-clinical
26
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
35